RxDoctor Payments Data

Melissa Moran

Nurse Practitioner · Scranton, PANPI 1427574839

Payments from drug & device makers

$2,051in general payments, 2019–2025

Across 80 payments — averaging $25.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$507
  • Dexcom, Inc.$282
  • Medtronic$262
  • Boehringer Ingelheim$242
  • Abbott$204
  • Tandem Diabetes Care, Inc.$156
  • plus $398 from 8 others

What the payments were for

  • Food & beverage$2,04099%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,051 in reported general payments places this provider in the 85th percentile of 4,059 nurse practitioner providers in Pennsylvania.

See all nurse practitioner providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$27,491
Medicare patients
252
Services billed
521

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide528$850,397
JardianceEmpagliflozin364$481,920
TrulicityDulaglutide183$278,422
MounjaroTirzepatide200$276,325
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog126$124,110
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/772$111,382
Tresiba Flextouch U-100Insulin Degludec74$83,314
Novolog FlexpenInsulin Aspart188$71,751
JanuviaSitagliptin Phosphate64$63,267
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog69$56,532
Tresiba Flextouch U-200Insulin Degludec41$55,938
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog22$38,890
TradjentaLinagliptin42$38,225
Lantus SolostarInsulin Glargine,hum.Rec.Anlog191$34,544
NovologInsulin Aspart72$31,897

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog, Fiasp$128$909,691614 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog$507$568,271423 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr, Synjardy$242$557,789450 claims
AbbVieSynthroid$30$6,33092 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,059 nurse practitioner providers in Pennsylvania.

Other nurse practitioner in Scranton

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →